Giulio Antonelli1, Elia Gigante1, Massimo Iavarone2, Paola Begini1, Angelo Sangiovanni2, Elsa Iannicelli3, Piero Biondetti4, Adriano M Pellicelli5, Lucia Miglioresi5, Paolo Marchetti6, Pietro Lampertico2, Massimo Marignani1. 1. Digestive and Liver Disease Unit, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy. 2. A. M. and A. Migliavacca Center for Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Maggiore Hospital, University of Milan, Milan, Italy. 3. Radiology Unit, Sant'Andrea University Hospital, School of Medicine and Psychology, Sapienza University of Rome, Rome, Italy. 4. Division of Radiology, Fondazione IRCCS Cà Granda Maggiore Hospital, Milan, Italy. 5. Liver Unit, San Camillo Forlanini Hospital, Rome, Italy. 6. Oncology Unit, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
Abstract
BACKGROUND: Sarcopenia has been associated with poor outcomes in patients with cirrhosis and solid tumours. OBJECTIVE: Analyse the influence of sarcopenia on survival and treatment duration in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. METHODS: We conducted a multicentre, retrospective study on 96 patients with advanced HCC treated with sorafenib, all with available abdominal computed tomography (CT) scan within 30 days from treatment start. Anthropometric, laboratory, treatment and follow-up data were collected. Sarcopenia was defined by reduced skeletal muscle index calculated from an L3 section CT image. RESULTS: Sarcopenia was present in 49% of patients. Patients were divided into two groups according to sarcopenia: age was significantly higher in the sarcopenic group (SG) (66 years (31-87) versus 72 years (30-84), p = 0.04], with no difference in other baseline characteristics. The SG showed shorter overall survival (OS) (39 (95% confidence interval (CI) 26-50) versus 61 (95% CI 47-77) weeks (p = 0,01)) and shorter time on treatment (12.3 (95% CI 8-19) versus 25.9 (95% CI 15-33) weeks (p = 0.0044)). At multivariate analysis, sarcopenia was independently associated to reduced OS (p = 0.03) and reduced time on treatment (p = 0.001). CONCLUSION: Sarcopenia is present in almost half of patients with advanced HCC, and is associated with reduced survival and reduced duration of oral chemotherapy.
BACKGROUND: Sarcopenia has been associated with poor outcomes in patients with cirrhosis and solid tumours. OBJECTIVE: Analyse the influence of sarcopenia on survival and treatment duration in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. METHODS: We conducted a multicentre, retrospective study on 96 patients with advanced HCC treated with sorafenib, all with available abdominal computed tomography (CT) scan within 30 days from treatment start. Anthropometric, laboratory, treatment and follow-up data were collected. Sarcopenia was defined by reduced skeletal muscle index calculated from an L3 section CT image. RESULTS: Sarcopenia was present in 49% of patients. Patients were divided into two groups according to sarcopenia: age was significantly higher in the sarcopenic group (SG) (66 years (31-87) versus 72 years (30-84), p = 0.04], with no difference in other baseline characteristics. The SG showed shorter overall survival (OS) (39 (95% confidence interval (CI) 26-50) versus 61 (95% CI 47-77) weeks (p = 0,01)) and shorter time on treatment (12.3 (95% CI 8-19) versus 25.9 (95% CI 15-33) weeks (p = 0.0044)). At multivariate analysis, sarcopenia was independently associated to reduced OS (p = 0.03) and reduced time on treatment (p = 0.001). CONCLUSION: Sarcopenia is present in almost half of patients with advanced HCC, and is associated with reduced survival and reduced duration of oral chemotherapy.
Authors: Puneeta Tandon; Michael Ney; Ivana Irwin; Mang M Ma; Leah Gramlich; Vincent G Bain; Nina Esfandiari; Vickie Baracos; Aldo J Montano-Loza; Robert P Myers Journal: Liver Transpl Date: 2012-10 Impact factor: 5.799
Authors: A Gökyer; A Küçükarda; O Köstek; M B Hacıoğlu; B S Sunal; N C Demircan; S Uzunoğlu; S Solak; K İşsever; I Çiçin; B Erdoğan Journal: Clin Transl Oncol Date: 2019-03-13 Impact factor: 3.405
Authors: Olivier Huillard; Anne Jouinot; Camille Tlemsani; Marcia S Brose; Jennifer Arrondeau; Gerold Meinhardt; Marc Fellous; Yoriko De Sanctis; Martin Schlumberger; Francois Goldwasser Journal: Thyroid Date: 2019-12 Impact factor: 6.568